Biogen price target raised to $445 from $400 at RBC Capital RBC Capital hiked its price target on Biogen as the firm thinks that the company's LINGO and Alzheimer's treatments are both reasoanble $5B-$10B opportunities. The firm keeps an Outperform rating.
Biogen price target raised to $443 from $376 at Stifel Stifel increased its price target on Biogen after listening to updates on the company's pipeline during its Q4 results conference call. The firm believes that the results of the clinical trials of Biogen's anti-LINGO in acute optic neuritis nd BIIB037 in Alzheimer’s disease were "highly positive." The firm says that the company's MS franchise is "safe and sound." It keeps a Buy rating on the shares.
Biogen price target raised to $410 from $383 at Citigroup Citigroup raised its price target for Biogen shares to $410 saying the company's 2015 guidance has upside. Citi keeps a Buy rating on Biogen following the company's Q4 results.
Biogen price target raised to $421 from $386 at Piper Jaffray Piper Jaffray raised its price target for Biogen shares to $421 citing the company's "solid" Q4 results and 2015 outlook. Piper reiterates an Overweight rating on the stock.
Leerink biotech analysts hold an analyst/industry conference call Biotech Analyst Schwartz discusses Biogen Idec BIIB037 and whether 2015 will be the year when Amyloid Beta is finally validated as a disease-modifying target in Alzheimer's Disease on an Analyst/Industry conference call to be held on February 3 at 2 pm.